Published in Proc Natl Acad Sci U S A on January 18, 2005
Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev (2010) 5.83
Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA (2008) 5.66
ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci U S A (2009) 2.93
Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab (2010) 2.53
Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide. Proc Natl Acad Sci U S A (2007) 2.04
Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor. Proc Natl Acad Sci U S A (2006) 1.93
Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor. Proc Natl Acad Sci U S A (2007) 1.93
ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes Dev (2013) 1.87
Transgenic overexpression of PKCε in the mouse prostate induces preneoplastic lesions. Cell Cycle (2011) 1.74
Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res (2009) 1.71
Diverse roles of androgen receptor (AR) domains in AR-mediated signaling. Nucl Recept Signal (2008) 1.47
Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells. Mol Cell Biol (2006) 1.46
IκBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor. BMC Cancer (2016) 1.39
FKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin A. Oncogene (2009) 1.29
Structure and function of steroid receptor AF1 transactivation domains: induction of active conformations. Biochem J (2005) 1.27
Androgen action and metabolism in prostate cancer. Mol Cell Endocrinol (2012) 1.25
Accumulating progenitor cells in the luminal epithelial cell layer are candidate tumor initiating cells in a Pten knockout mouse prostate cancer model. PLoS One (2009) 1.24
The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens. BMC Cell Biol (2008) 1.21
Androgen receptor splice variant AR3 promotes prostate cancer via modulating expression of autocrine/paracrine factors. J Biol Chem (2013) 1.18
Identification of novel androgen receptor target genes in prostate cancer. Mol Cancer (2007) 1.15
The immunophilin ligands cyclosporin A and FK506 suppress prostate cancer cell growth by androgen receptor-dependent and -independent mechanisms. Endocrinology (2007) 1.12
Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. FASEB J (2010) 1.11
Natural disordered sequences in the amino terminal domain of nuclear receptors: lessons from the androgen and glucocorticoid receptors. Nucl Recept Signal (2007) 1.08
Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic. Cancer Metastasis Rev (2013) 1.08
Epidermal-growth-factor-dependent phosphorylation and ubiquitinylation of MAGE-11 regulates its interaction with the androgen receptor. Mol Cell Biol (2008) 1.07
Androgen receptor (AR) physiological roles in male and female reproductive systems: lessons learned from AR-knockout mice lacking AR in selective cells. Biol Reprod (2013) 1.02
Prostate cancer: Re-focusing on androgen receptor signaling. Int J Biochem Cell Biol (2007) 0.99
Androgen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo. Int J Cancer (2007) 0.99
Profiling human androgen receptor mutations reveals treatment effects in a mouse model of prostate cancer. Mol Cancer Res (2008) 0.94
Current mouse and cell models in prostate cancer research. Endocr Relat Cancer (2013) 0.92
Dicer ablation impairs prostate stem cell activity and causes prostate atrophy. Stem Cells (2010) 0.90
Androgen receptor drives cellular senescence. PLoS One (2012) 0.89
Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors. Oncotarget (2013) 0.88
Androgen receptor (AR) pathophysiological roles in androgen-related diseases in skin, bone/muscle, metabolic syndrome and neuron/immune systems: lessons learned from mice lacking AR in specific cells. Nucl Recept Signal (2013) 0.88
Androgen receptor gene mutation, rearrangement, polymorphism. Transl Androl Urol (2013) 0.87
Differential regulation of insulin-like growth factor-I receptor gene expression by wild type and mutant androgen receptor in prostate cancer cells. Mol Cell Endocrinol (2010) 0.87
Hormones and prostate carcinogenesis: Androgens and estrogens. J Carcinog (2011) 0.86
Expression of androgen receptor splice variants in clinical breast cancers. Oncotarget (2015) 0.85
SRC: marker or actor in prostate cancer aggressiveness. Front Oncol (2014) 0.83
A peptide against soluble guanylyl cyclase α1: a new approach to treating prostate cancer. PLoS One (2013) 0.83
A novel androgen receptor amino terminal region reveals two classes of amino/carboxyl interaction-deficient variants with divergent capacity to activate responsive sites in chromatin. Endocrinology (2009) 0.81
Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer. Adv Urol (2012) 0.81
New developments in the treatment of castration resistant prostate cancer. Asian J Androl (2014) 0.81
The N-terminal domain of the androgen receptor drives its nuclear localization in castration-resistant prostate cancer cells. J Steroid Biochem Mol Biol (2014) 0.80
Androgen receptor footprint on the way to prostate cancer progression. World J Urol (2011) 0.80
Probasin promoter-driven expression of ID1 is not sufficient for carcinogenesis in rodent prostate. J Histochem Cytochem (2009) 0.80
Differentially expressed androgen-regulated genes in androgen-sensitive tissues reveal potential biomarkers of early prostate cancer. PLoS One (2013) 0.80
Androgen receptor variants and prostate cancer in humanized AR mice. J Steroid Biochem Mol Biol (2007) 0.79
Maintenance of androgen receptor inactivation by S-nitrosylation. Cancer Res (2013) 0.78
Statin derivatives as therapeutic agents for castration-resistant prostate cancer. Cancer Lett (2016) 0.77
Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer. Oncotarget (2015) 0.77
Bicalutamide-activated oncolytic adenovirus for the adjuvant therapy of high-risk prostate cancer. Cancer Gene Ther (2013) 0.77
COP9 subunits 4 and 5 target soluble guanylyl cyclase α1 and p53 in prostate cancer cells. Mol Endocrinol (2014) 0.76
Androgen receptor gene polymorphisms and alterations in prostate cancer: of humanized mice and men. Mol Cell Endocrinol (2011) 0.76
Effect of small molecules modulating androgen receptor (SARMs) in human prostate cancer models. PLoS One (2013) 0.75
CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res (1994) 392.47
The influence of finasteride on the development of prostate cancer. N Engl J Med (2003) 24.45
Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90
The development of androgen-independent prostate cancer. Nat Rev Cancer (2001) 11.88
Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A (1995) 8.16
Metastatic prostate cancer in a transgenic mouse. Cancer Res (1996) 4.02
Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate (2003) 3.44
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res (1994) 3.43
A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res (2001) 3.37
Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res (1997) 3.37
Biological control through regulated transcriptional coactivators. Cell (2004) 3.05
Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer (2004) 3.03
From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci U S A (1999) 3.00
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res (1999) 2.96
Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem (2000) 2.60
A history of prostate cancer treatment. Nat Rev Cancer (2002) 2.46
Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci U S A (2001) 2.44
HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res (2000) 2.25
The androgen receptor gene mutations database (ARDB): 2004 update. Hum Mutat (2004) 2.25
The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol Endocrinol (1994) 2.22
The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol (1992) 2.21
Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res (1996) 1.78
An androgen receptor NH2-terminal conserved motif interacts with the COOH terminus of the Hsp70-interacting protein (CHIP). J Biol Chem (2004) 1.36
Conformational analysis of the androgen receptor amino-terminal domain involved in transactivation. Influence of structure-stabilizing solutes and protein-protein interactions. J Biol Chem (2002) 1.22
Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res (2001) 1.17
Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol (1998) 1.10
Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. J Urol (1999) 1.08
Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer. J Biol Chem (2000) 1.07
Pattern of somatic androgen receptor gene mutations in patients with hormone-refractory prostate cancer. Lab Invest (2002) 1.06
Inhibition of growth and induction of apoptosis by androgens of a variant of LNCaP cell line. J Steroid Biochem Mol Biol (2000) 0.96
Intermittent androgen suppression for prostate cancer: rationale and clinical experience. Prostate Cancer Prostatic Dis (1998) 0.93
Prostate cancer: a dynamic illness with shifting targets. Lancet Oncol (2003) 0.92
Steroid hormones, polypeptide growth factors, hormone refractory prostate cancer, and the neuroendocrine phenotype. J Cell Biochem (2004) 0.91
Characterization of the FGF axis and identification of a novel FGFR1iiic isoform during prostate cancer progression in the TRAMP model. Prostate Cancer Prostatic Dis (1999) 0.88
Positional dependence of the effects of negatively charged Glu side chains on the stability of two-stranded alpha-helical coiled-coils. J Pept Sci (1997) 0.86
Enforced expression of FGF-7 promotes epithelial hyperplasia whereas a dominant negative FGFR2iiib promotes the emergence of neuroendocrine phenotype in prostate glands of transgenic mice. Differentiation (2002) 0.86
Role of conserved hydrophobic amino acids in androgen receptor AF-1 function. J Mol Endocrinol (2003) 0.85
Intermittent complete androgen blockade in metastatic prostate cancer. Eur Urol (1999) 0.82
Immunization against luteinizing hormone-releasing hormone fusion proteins does not decrease prostate cancer in the transgenic adenocarcinoma mouse prostate model. Exp Biol Med (Maywood) (2003) 0.78
Pten dose dictates cancer progression in the prostate. PLoS Biol (2003) 7.62
NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity (2008) 5.35
Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res (2006) 4.50
Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate (2003) 3.44
Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res (2007) 3.25
Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer (2004) 3.03
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Aggregation of STIM1 underneath the plasma membrane induces clustering of Orai1. Biochem Biophys Res Commun (2006) 2.89
Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. Cancer Cell (2012) 2.84
Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell (2007) 2.48
Global gene expression analysis of reactive stroma in prostate cancer. Clin Cancer Res (2009) 2.34
Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res (2008) 2.18
Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS One (2008) 2.18
Variable stoichiometry of the TatA component of the twin-arginine protein transport system observed by in vivo single-molecule imaging. Proc Natl Acad Sci U S A (2008) 2.09
SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res (2005) 2.07
Age-related DNA methylation changes in normal human prostate tissues. Clin Cancer Res (2007) 2.02
Retracted Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells. Cancer Res (2009) 2.00
Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res (2009) 1.98
Role of the Escherichia coli Tat pathway in outer membrane integrity. Mol Microbiol (2003) 1.96
Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer (2007) 1.94
Bone morphogenetic protein 2 functions via a conserved signaling pathway involving Wnt4 to regulate uterine decidualization in the mouse and the human. J Biol Chem (2007) 1.91
Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res (2004) 1.77
Structural and functional consequences of glutamine tract variation in the androgen receptor. Hum Mol Genet (2004) 1.74
Coordinating assembly and export of complex bacterial proteins. EMBO J (2004) 1.73
Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer. PLoS One (2008) 1.72
Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia. Prostate (2004) 1.71
Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development. J Natl Cancer Inst (2013) 1.70
The current state of preclinical prostate cancer animal models. Prostate (2008) 1.68
Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer. J Immunol (2007) 1.67
Wnt/β-catenin signaling accelerates mouse lung tumorigenesis by imposing an embryonic distal progenitor phenotype on lung epithelium. J Clin Invest (2011) 1.67
Social cognition and face processing in schizophrenia. Br J Psychiatry (2004) 1.67
Mouse lacking COUP-TFII as an animal model of Bochdalek-type congenital diaphragmatic hernia. Proc Natl Acad Sci U S A (2005) 1.65
Paths of FGFR-driven tumorigenesis. Cell Cycle (2009) 1.63
Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells. Cancer Res (2005) 1.62
Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway. Cancer Res (2006) 1.61
Cellular senescence in the pathogenesis of benign prostatic hyperplasia. Prostate (2003) 1.61
A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease. Int J Cancer (2012) 1.60
The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res (2004) 1.59
Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. Cancer Res (2008) 1.58
Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression. Cancer Res (2008) 1.54
Steroid receptor coactivator 2 is critical for progesterone-dependent uterine function and mammary morphogenesis in the mouse. Mol Cell Biol (2006) 1.52
The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer. Cancer Res (2004) 1.51
Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis. Cancer Res (2007) 1.49
Conserved network of proteins essential for bacterial viability. J Bacteriol (2009) 1.48
Behaviour of topological marker proteins targeted to the Tat protein transport pathway. Mol Microbiol (2002) 1.47
Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling. PLoS One (2008) 1.46
Promotion of lung carcinogenesis by chronic obstructive pulmonary disease-like airway inflammation in a K-ras-induced mouse model. Am J Respir Cell Mol Biol (2008) 1.44
Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (2006) 1.43
The nuclear orphan receptor COUP-TFII is required for limb and skeletal muscle development. Mol Cell Biol (2004) 1.39
Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. Clin Cancer Res (2010) 1.38
Phosphorylation of the Pseudomonas aeruginosa response regulator AlgR is essential for type IV fimbria-mediated twitching motility. J Bacteriol (2002) 1.37
Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. Cancer Res (2005) 1.36
A new three-dimensional ultrasound microimaging technology for preclinical studies using a transgenic prostate cancer mouse model. Cancer Res (2005) 1.34
Haploinsufficiency of chicken ovalbumin upstream promoter transcription factor II in female reproduction. Mol Endocrinol (2005) 1.33
The contribution of different androgen receptor domains to receptor dimerization and signaling. Mol Endocrinol (2008) 1.32
Targeting Aurora kinases for the treatment of prostate cancer. Cancer Res (2006) 1.31
Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. Eur J Immunol (2005) 1.29
Structural analysis of substrate binding by the TatBC component of the twin-arginine protein transport system. Proc Natl Acad Sci U S A (2009) 1.29
Stable-isotope labeling with amino acids in nematodes. Nat Methods (2011) 1.28
Cutting Edge: Tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells. J Immunol (2009) 1.26
The activation function-1 domain of Nur77/NR4A1 mediates trans-activation, cell specificity, and coactivator recruitment. J Biol Chem (2002) 1.25
Peroxisome proliferator-activated receptor gamma is a target of progesterone regulation in the preovulatory follicles and controls ovulation in mice. Mol Cell Biol (2008) 1.24
Regulated expression of Wnts and Frizzleds at specific stages of follicular development in the rodent ovary. Endocrinology (2002) 1.24
Conditional deletion of Rb causes early stage prostate cancer. Cancer Res (2004) 1.23
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. Proc Natl Acad Sci U S A (2008) 1.22
Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model. Neoplasia (2007) 1.22
Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model. Cancer Res (2007) 1.22
Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha. Cancer Res (2007) 1.20
Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. FASEB J (2007) 1.19
Epithelial progesterone receptor exhibits pleiotropic roles in uterine development and function. FASEB J (2011) 1.19
Aprataxin forms a discrete branch in the HIT (histidine triad) superfamily of proteins with both DNA/RNA binding and nucleotide hydrolase activities. J Biol Chem (2006) 1.19
Activation of NF-{kappa}B by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4. Cancer Res (2010) 1.18
Probing the specificity of binding to the major nuclear localization sequence-binding site of importin-alpha using oriented peptide library screening. J Biol Chem (2010) 1.18
Genetic ablation of the amplified-in-breast cancer 1 inhibits spontaneous prostate cancer progression in mice. Cancer Res (2007) 1.18
Inducible prostate intraepithelial neoplasia with reversible hyperplasia in conditional FGFR1-expressing mice. Cancer Res (2003) 1.18
Stromal antiapoptotic paracrine loop in perineural invasion of prostatic carcinoma. Cancer Res (2006) 1.17
Granulosa cell-expressed BMPR1A and BMPR1B have unique functions in regulating fertility but act redundantly to suppress ovarian tumor development. Mol Endocrinol (2010) 1.17
Cysteine scanning mutagenesis and disulfide mapping studies of the TatA component of the bacterial twin arginine translocase. J Biol Chem (2007) 1.16
Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Res (2003) 1.16
Functional neoangiogenesis imaging of genetically engineered mouse prostate cancer using three-dimensional power Doppler ultrasound. Cancer Res (2007) 1.16
Diagnostic utility of LunX mRNA in peripheral blood and pleural fluid in patients with primary non-small cell lung cancer. BMC Cancer (2008) 1.15
Identification of novel androgen receptor target genes in prostate cancer. Mol Cancer (2007) 1.15
Maternal heparin-binding-EGF deficiency limits pregnancy success in mice. Proc Natl Acad Sci U S A (2007) 1.15
beta1A integrin expression is required for type 1 insulin-like growth factor receptor mitogenic and transforming activities and localization to focal contacts. Cancer Res (2005) 1.14
Natural variation of drought response in Brachypodium distachyon. Physiol Plant (2010) 1.14
A working group classification of focal prostate atrophy lesions. Am J Surg Pathol (2006) 1.13
Role of epithelial cell fibroblast growth factor receptor substrate 2alpha in prostate development, regeneration and tumorigenesis. Development (2008) 1.13
Cysteine-scanning mutagenesis and disulfide mapping studies of the conserved domain of the twin-arginine translocase TatB component. J Biol Chem (2006) 1.12
The AF-1 domain of the orphan nuclear receptor NOR-1 mediates trans-activation, coactivator recruitment, and activation by the purine anti-metabolite 6-mercaptopurine. J Biol Chem (2003) 1.12
Development and regeneration of Sox2+ endoderm progenitors are regulated by a Hdac1/2-Bmp4/Rb1 regulatory pathway. Dev Cell (2013) 1.12
Differential expression and/or activation of P38MAPK, erk1/2, and jnk during the initiation and progression of prostate cancer. Prostate (2003) 1.12